All times are in the Central European Summer Time (CEST).
If you need another time zone, this website might be useful to you: https://www.worldtimebuddy.com/
Topics
Meeting category
Date(s)
19 Sep 2022 - 20 Sep 2022
Program Language
English
Location
Barcelona,
Spain
Meeting type
Hybrid
Organizer
International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022
Related Enduring Materials
Enduring Materials
Day 1: Monday, 19 September 2022
Opening of the Workshop - 10:00
Opening Lecture: PrEP and Monkeypox in Spain
Opening Session: Clinical Pharmacology of COVID-19 and Emerging Viruses -
Alice Tseng, B.Sc.Phm., PharmD, FCSHP, AAHIVP
Chairs
Toronto General Hospital, University of Toronto, Canada
Emerging Strategies for Treating and Preventing Monkeypox
Current COVID-19 Therapies and Variants
DDIs Relevant for COVID-19 Therapeutic Agents & Implementation Challenges
Discussion
Session 1: Abstract-Driven Session -
Chair
#1: Predicting pharmacokinetics of nirmatrelvir/ritonavir in pregnant patients using physiologically based pharmacokinetic modelling.
Erica Leertouwer
Radboud Institute of Health Sciences, the Netherlands
#2: Pharmacokinetics of sotrovimab, a monoclonal antibody for early treatment of mild-to-moderate COVID-19
Asma El-Zailik
Vir Biotechnology, United States
#3: Pharmacokinetics of the small interfering RNA (siRNA) JNJ-73763989 and capsid assembly modulator (CAM) JNJ-56136379 in patients with chronic hepatitis B (CHB): REEF-1 and REEF-2 pharmacokinetic substudy (No 3)
Thomas Kakuda
Alios BioPharma, United States
#4: A Phase 1 Drug-Drug Interaction Study to Investigate the Potential Interaction Between ATI-2173 When Co-administered With Midazolam or Clarithromycin in Healthy Subjects
Myreen Tomas
Antios Therapeutics, United States
Discussion
Session 2: Debate - Is the End in Sight for Oral PrEP Therapies? -
Heather-Marie Schmidt, BMedSc (Hon), MPH, PhD
Chairs
Opening Words
Voting
PRO Healthcare Provider: Long-Acting Injectables for PrEP
CON Healthcare Provider: Oral Daily and/or On Demand PrEP
Community Perspective
Policy Perspective
UNAIDS Regional Office for Asia and the Pacific, Thailand and the Global HIV, Hepatitis and STIs Programme, World Health Organisation, Switzerland
Discussion with the Audience
Rebuttal (3 min/group - PRO and CON)
Voting
#5: A New Algorithm to Improve Adherence Classification Using Dried Blood Spots for Daily and Event-Driven PrEP
Aaron Devanathan
University of Pittsburgh, United States
#6: Long-acting Cabotegravir Pharmacokinetics With and Without Oral Lead-in for HIV PrEP
Kelong Han
GlaxoSmithKline, United States
Session 3: Pharmacological Developments With New & Old Viral Infections -
Chair
Pharmacology Considerations of Future ART/PrEP Regimens
Recent Developments in Antivirals Against Herpes Simplex Virus Infection
What’s on the Horizon for Direct Acting Antivirals for Hepatitis B?
Discussion
ViiV Symposium: Early Pharmacology of Cabotegravir - Implications for Treatment and Prevention -
Chairs
Opening Words
Long-acting Cabotegravir for Treatment and Prevention: When Are You Protected?
Clinical Implications of Cabotegravir Plasma Levels
The Non-adherent Patient: A Good or Bad Candidate for CAB+RPV?
Discussion
Closure of the Symposium
Day 2: Tuesday, 20 September 2022
Session 4: Opening Pharmacological Considerations in Key Populations -
Catia Marzolini, PharmD, PhD
Chairs
Age-Related Changes in Pharmacokinetics and Pharmacodynamics
University Hospital of Basel, University Hospital of Lausanne, Switzerland; University of Liverpool, United Kingdom
Pharmacology Pearls for Managing Absorption and Swallowing Difficulties
Optimization of Pharmacology Studies and DDIs in Pregnant and Lactating Individuals
Discussion
Session 5: Abstract-Driven Session -
Chair
#7: Physiologically-Based Pharmacokinetic Modelling of Long-Acting Cabotegravir in Pregnancy Suggests That Dose Adjustment Might Not Be Necessary
Shakir Atoyebi
University of Liverpool, United Kingdom
#8: Pharmacokinetics of First-line Tuberculosis Drugs in Pregnant and Postpartum Women without HIV and Women with HIV on Efavirenz-based Antiretroviral Treatment
Marije Van Schalkwyk
Stellenbosch University / Tygerberg Hospital, South Africa
#9: TFVdp in Cervical Tissue in Pre- And Post- Menopausal Women on TAF and TDF
Alyssa Lantz
University Of Minnesota, United States
#10: Doravirine Exposure in Obese Population Living With HIV Infection (Double Study): Data From Physiologically-Based Pharmacokinetics Modelling and Real-Life Patients
Leena Zino
Radboudumc, the Netherlands
Discussion
Charles Boucher Memorial Lecture -
Chair
Pharmacokinetics of mAbs in Prevention, Treatment and Cure of Viral Infections
#11: Plasma, Intracellular and Lymph node Antiretroviral Concentrations and HIV DNA Change in Patients Treated During Primary HIV Infection: Results from the INACTION P25 Study
Amedeo De Nicolò
Università Degli Studi Di Torino, Italy
Session 6: Abstract-Driven Session -
Catia Marzolini, PharmD, PhD
Caroline Solas Chesneau, PharmD, PhD
Chairs
University Hospital of Basel, University Hospital of Lausanne, Switzerland; University of Liverpool, United Kingdom
University Hospital of La Timone, Aix-Marseille University, France
Endogenous Biomarker Informed Approach to Assess Potential for Transporter Mediated Drug-Drug Interactions: Concepts, Applications, Knowledge Gaps
#12: Deep Learning Ensemble Classifier to Predict Drug-Drug Interaction
Thao Pham
University Of Liverpool, United Kingdom
#13: Population Pharmacokinetics of the Levonorgestrel Implant in Combination With Four Antiretroviral Therapies
Michelle Pham
University of Nebraska Medical Center, United States
Discussion
Session 7: New Drug Detection and Delivery Technologies -
Chairs
Multipurpose Prevention Technologies (MPTs) For Prevention of HIV and Pregnancy
Strategies to Improve Delivery to Reservoirs as Targets for Long-Acting Antivirals
Point of Care Tests for Drug Level Testing: Where Are We?
#14: Tenofovir Diphosphate in Dried Blood Spots in Persons With HIV Taking Tenofovir Alafenamide as Digital Pills: Preliminary Data From the QUANTI-TAF Study
Ryan Coyle
University of Colorado-AMC, United States
Discussion
Session 8: Roundtable Discussion: Unexpected Pitfalls of Long-Acting Agents -
Chairs
Short Talk: Islatravir Toxicity
Short Talk: Cabotegravir/Rilpivirine Failures Despite Adherence
Short Talk: Lenacapavir Considerations
Panel Discussion
Overview
Welcome!
The International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022 took place as a hybrid workshop at the Sercotel Caspe Hotel in Barcelona, Spain, from 19-20 September 2022. Delegates were able to attend either in person in Barcelona or virtually from their computer.
This workshop was the 23rd Edition of the Antiviral PK meeting. A truly historic and important workshop dedicated to understanding the clinical pharmacology of antiviral therapy that is pivotal to designing optimal treatment and prevention strategies.
The International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2023 will take place as a hybrid workshop from 11-13 September 2023.
The International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs gathers leading experts to discuss all aspects of the optimal use of antiviral therapy including drug-drug interactions, pharmacokinetics of investigational and existing drugs, pharmacodynamics, drug dosing in underrepresented populations, post-marketing surveillance, and regulatory considerations.
Program Chairs
General Information
COVID-19 Update
Responding to the changing COVID-19 situation, the International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022 will be held as a hybrid meeting allowing both in-person and virtual attendance. This workshop format is an optimal solution in light of the current circumstances.
We are available to answer any questions or concerns that you may have about your participation. For more information, please contact Eva Vamvounaki via Eva.Vamvounaki@amededu.com.
We are available to answer any questions or concerns that you may have about your participation. For more information, please contact Eva Vamvounaki via Eva.Vamvounaki@amededu.com.
Venue
This year's edition will take place in Barcelona, Spain at the Hotel Sercotel Caspe. Contact us for a discount code or more information should you wish to combine your attendance with accommodation (Eva Vamvounaki via Eva.Vamvounaki@amededu.com).
Address:
Hotel Sercotel Caspe
Carrer de Casp, 103
08013 Barcelona
Spain
Official Website:
https://en.sercotelcaspe.com/
Address:
Hotel Sercotel Caspe
Carrer de Casp, 103
08013 Barcelona
Spain
Official Website:
https://en.sercotelcaspe.com/
Networking Dinner
The networking dinner will take place at the Agüelo Taberna in Barcelona, Spain.
Make sure to register for the dinner when registering for the workshop to connect with your colleagues and the great faculty.
Dinner venue: Agüelo Taberna
Address: Carrer d'Avinyó, 37, 08002 Barcelona, Spain
Website: https://aguelotaberna.es/
Make sure to register for the dinner when registering for the workshop to connect with your colleagues and the great faculty.
Dinner venue: Agüelo Taberna
Address: Carrer d'Avinyó, 37, 08002 Barcelona, Spain
Website: https://aguelotaberna.es/
Who Should Attend?
- Clinical pharmacologists;
- Pharmacists;
- Clinicians/ researchers;
- Industry representatives;
- Regulatory scientists;
- Government representatives;
- Post-graduate students; and
- Others involved in the clinical pharmacology of antiviral therapy.
- Pharmacists;
- Clinicians/ researchers;
- Industry representatives;
- Regulatory scientists;
- Government representatives;
- Post-graduate students; and
- Others involved in the clinical pharmacology of antiviral therapy.
Meeting Objectives
This meeting aims to:
- Gather experts involved in clinical pharmacology from different disciplines in an interactive workshop setting;
- Provide a platform for presentation and discussion of the latest developments in the field;
- Share information on ongoing pharmacological studies; and
- Stimulate discussion and consensus on best practices.
- Gather experts involved in clinical pharmacology from different disciplines in an interactive workshop setting;
- Provide a platform for presentation and discussion of the latest developments in the field;
- Share information on ongoing pharmacological studies; and
- Stimulate discussion and consensus on best practices.
Learning Objectives
After participating in this activity, participants will be able to:
- Outline new developments and the clinical pharmacology of antiviral therapies for HIV, COVID-19, Hepatitis, and other viruses;
- Reflect on new Drug Detection / Delivery Technologies; and
- Describe pharmacological considerations in key populations.
- Outline new developments and the clinical pharmacology of antiviral therapies for HIV, COVID-19, Hepatitis, and other viruses;
- Reflect on new Drug Detection / Delivery Technologies; and
- Describe pharmacological considerations in key populations.
Certificate of Attendance
A certificate of attendance will be sent to participants after they have successfully completed the program and post-meeting survey.
Language
The official language of the workshop is English. Translation will not be provided.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.
Liability and Insurance
By registering for the workshop, participants agree that the organizers do not accept responsibility for medical, travel, or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official workshop sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided the speaker has given permission to do so.
Code of Conduct
All attendees, speakers, co-organizers, partners, endorsers, suppliers, volunteers, and employees at any of our programs are expected to observe our Code of Conduct. We cannot tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. All participants of VE and AME-organized programs are expected to treat others with dignity and respect at all times.
Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Registration
Registration is now closed.
-
Registration for International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs 2022 is now closed.
-
The registration fee includes access to all (livestream) sessions during the event (19-20 September), as well as access to all presentation materials and recordings three weeks after the event (22 September - 12 October) on the virtual portal.
-
Payment can only be made by credit card. If this is not possible for you, please contact the Conference Secretariat via eva.vamvounaki@amededu.com.
-
If you have financial concerns or are eligible for a discount, please contact the conference secretariat via eva.vamvounaki@amededu.com.
Fees & Conditions
|
Academia In-Person Attendance |
Academia Virtual Attendance |
Industry*** |
|
|
Early Fee (payment before/on 13 March 2022) |
€ 495.00 |
€ 247.50 |
€ 1,645.00 |
|
Regular Fee (payment before/on 3 June 2022) |
€ 695.00 |
€ 347.50 |
€ 1,945.00 |
|
Late Fee (payment before/on 18 September 2022) |
€ 895.00 |
€ 447.50 |
€ 2,045.00 |
|
Same-Day Fee* (payment from 19 September) |
€ 995.00 |
€ 497.50 |
€ 2,145.00 |
|
Early-career investigators and/or academia from Resource-Limited Settings (RLS)**, NGO representatives, government representatives, and community advocates. |
50% Off Current Academia Fee |
|
Representatives of sponsoring industry / endorsing organizations *** |
Please contact the conference secretariat |
* To register on the workshop dates and revisit the recordings of the live stream on the virtual portal
** Countries included in the low-income and lower-middle-income economies of the World Bank Classification.
*** Industry and endorser representatives may receive a discount based on the level of support provided to the event. For more support and registration information, please contact us via Rikke.Rode@amededu.com.
If you have financial concerns or are eligible for a discount, please contact the conference secretariat via eva.vamvounaki@amededu.com.
Important
- We strongly advise that you register early to secure your slot.
- Submission of your online registration does not guarantee that your registration has been accepted. Your registration is final when full payment has been received (if applicable) and a confirmation of your registration has been sent.
- Virology Education reserves the right to cancel improper registrations. Claims for a refund will not be honoured.
Registration Fee Includes
- Access to all scientific sessions
- Access to enduring materials
- (Virtual) workshop materials
- Access to enduring materials
- (Virtual) workshop materials
Early-Career Professional
To be eligible as an early-career professional, one should be:
- a current Master/PhD student; OR
- have obtained an MD/PharmD/PhD degree in the last five years.
An application form (available below) needs to be completed by a supervisor and received by the Virology Education secretariat at least two weeks prior to the start of the summit.
- a current Master/PhD student; OR
- have obtained an MD/PharmD/PhD degree in the last five years.
An application form (available below) needs to be completed by a supervisor and received by the Virology Education secretariat at least two weeks prior to the start of the summit.
Payment
By credit card only: online or by written authorization.
Please contact the conference secretariat via eva.vamvounaki@amededu.com if you need to make alternative arrangements.
Please contact the conference secretariat via eva.vamvounaki@amededu.com if you need to make alternative arrangements.
Sponsored Attendance
If you are invited by a pharmaceutical or diagnostic company, or if your registration is organized by a travel agency, please do not register online. The sponsoring company will be asked to register you via the conference secretariat.
Group Registration
For registration of groups larger than 5 participants, please contact the Conference Secretariat at eva.vamvounaki@amededu.com.
Media Registration
In order to register as a media participant for the workshop, the conference secretariat needs to receive:
1. Proof of accreditation
2. Valid identification (e.g. passport)
3. A letter from your assignment giver stating the details of your assignment (e.g. editor)
4. At least 3 previous written assignments in recognized outlets on HIV. If you are a freelance journalist, the assignments can be from different (recognizable) news outlets. Links to online publications are accepted
5. The website of the publication(s)/blog(s) that will be featuring your story on this workshop
A free or reduced registration fee may apply for accredited media participants depending on availability. Preference will be given to credible print and online news sources. Please contact the conference secretariat for registration conditions.
We would like to receive a copy of your workshop report/ article once it is finalized.
All credentials will be verified by the Organizing Committee of the Workshop. Media representatives are kindly requested to register by sending the above-mentioned information to info@amededu.com.
Important: Media is restricted to the written press. Recording on film or photo is not allowed. Virology Education will request a copy of the written piece once it is finalized. Media representatives must also agree to abide by the 2022 embargo policy.
1. Proof of accreditation
2. Valid identification (e.g. passport)
3. A letter from your assignment giver stating the details of your assignment (e.g. editor)
4. At least 3 previous written assignments in recognized outlets on HIV. If you are a freelance journalist, the assignments can be from different (recognizable) news outlets. Links to online publications are accepted
5. The website of the publication(s)/blog(s) that will be featuring your story on this workshop
A free or reduced registration fee may apply for accredited media participants depending on availability. Preference will be given to credible print and online news sources. Please contact the conference secretariat for registration conditions.
We would like to receive a copy of your workshop report/ article once it is finalized.
All credentials will be verified by the Organizing Committee of the Workshop. Media representatives are kindly requested to register by sending the above-mentioned information to info@amededu.com.
Important: Media is restricted to the written press. Recording on film or photo is not allowed. Virology Education will request a copy of the written piece once it is finalized. Media representatives must also agree to abide by the 2022 embargo policy.
Disclaimer
This meeting is intended for educational purposes only and aims to offer participants the opportunity to share information. The organizing secretariat of this forum, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this forum. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the forum. In case of cancellation of the forum due to unforeseen circumstances, Virology Education cannot be held responsible for any applicable expenses made for travel, accommodation, visa applications, etc.
Liability and Insurance
By registering for the meeting, participants agree that the organizers do not accept responsibility for medical, travel, or personal insurance. Participants are advised to take out their own insurance policies.
Cancellation Policy
In case of cancellation, the following refunds are applicable:
- Cancellation before/on 18 August 2022: 50% refund (minus an administration fee of €40)
- Cancellation after 18 August 2022: Unfortunately, no refund will be given
Should you be unable to attend the forum, a substitute delegate is always welcome at no extra charge provided that a letter of authorization from the original participant has been received and the conference secretariat has been notified of the name of the substitute delegate before 5 September 2022. A statement (email/letter) of your cancellation must be sent to Virology Education.
- Cancellation before/on 18 August 2022: 50% refund (minus an administration fee of €40)
- Cancellation after 18 August 2022: Unfortunately, no refund will be given
Should you be unable to attend the forum, a substitute delegate is always welcome at no extra charge provided that a letter of authorization from the original participant has been received and the conference secretariat has been notified of the name of the substitute delegate before 5 September 2022. A statement (email/letter) of your cancellation must be sent to Virology Education.
Committees
Organizing Committee
The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.
Scientific Committee
The members of the Scientific Committee are hand-picked by the Organizing Committee and the conference secretariat based on their significant contributions and commitment to the field. They assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts and play an active role during the workshop as moderators and/or chairs of sessions.
- Su-Young Choi, PharmD, PhD - Food and Drug Administration, United States
- Angela Colbers, PhD - Radboud University Medical Center, the Netherlands
- Rodolphe Garraffo, MD - Hopital Pasteur Nice, France
- David Haas, MD - Vanderbilt University Medical Center, United States
- Saye Khoo, MD - University of Liverpool, United Kingdom
- Mohammed Lamorde, MD - Infectious Diseases Institute, Uganda
- Lawrence Lee, MBBS, PhD - National University of Singapore, Singapore
- Minh Patrick Lê, PhD - Hôpital Bichat-Claude Bernard, France
- Catia Marzolini, PharmD, PhD - University Hospital Basel & University of Liverpool, United Kingdom
- Kimberly Struble, PharmD - Food and Drug Administration, United States
- Steve Taylor, MRCP, PhD - Birmingham Heartlands Hospital, United Kingdom
- Catriona Waitt, MBChB, PhD - University of Liverpool, United Kingdom
Academic Advisory Board
The members of the Academic Advisory Board (AAB) are former members of the OC and remain active the in planning of the program for the next year. Members of the current OC are selected from this group.
- David Back, PhD - University of Liverpool, United Kingdom
- Terrence Blaschke, MD - Stanford University School of Medicine, United States
- David Burger, MD, PhD - Radboud University Medical Center, the Netherlands
- Giovanni Di Perri, MD, PhD - University of Torino, Italy
- Courtney Fletcher, PharmD - University of Nebraska Medical Center, United States
- Charles Flexner, MD - Johns Hopkins University, United States
- Angela Kashuba, PharmD - University of North Carolina at Chapel Hill, United States
- Jennifer Kiser, PharmD, PhD - University of Colorado, United States
- Jürgen Rockstroh, MD - University of Bonn, Germany
- Jonathan Schapiro, MD - National Hemophilia Center, Sheba Medical Center, Israel
Industry Liaison Board
The Industry Liaison Board, consisting of leading medical scientists of the pharmaceutical industry, is asked to give input and suggestions that help the Organizing Committee in planning the workshop and providing support on topics of interest and innovative suggestions to optimize audience participation. The Industry Liaison Board assists the Organizing Committee by suggesting the most current and critical topics to bring the audience up-to-date on the most current research in the pharmaceutical industry in related disciplines.
- Daria Hazuda - Merck
- Thomas Kakuda - Alios BioPharma
- Charles LaPorte - Janssen Biologics
- Wei Liu - AbbVie
- Parul Patel - ViiV Healthcare
- Marco Siccardi - Labcorp
- Manoli Vourvahis - Pfizer
Abstract
Abstracts
- Abstract Submission is now closed.
- Registration fees are waived for healthcare professionals from RLS and early-career professionals with an accepted abstract. A 50% discount is offered to healthcare professionals from RLS and early-career professionals without an accepted abstract. The requirements for the application are specified under "Registration".
- Abstracts can be submitted in English.
Abstract Categories
We invite you to submit your latest study and data in any of the below categories:
-
Drug-Drug Interactions
-
Novel Drugs and Formulations
-
Pharmacogenetics
-
Pharmacokinetics during Pregnancy and Other Key Populations
-
PK/PD of Drug Efficacy and Toxicity (including TDM)
-
Cellular and Tissue Pharmacokinetics
Terms and Conditions
By submitting an abstract to a meeting organized by Virology Education BV (VE) or Academic Medical Education BV (AME), the abstract submitter hereby agrees to the terms and conditions.
The terms and conditions can be viewed here.
Notification of Abstract Acceptance and Presentation Format
It is the responsibility of the corresponding/ presenting author to inform all co-authors of the abstract’s status. We aim to send out notifications at least 1.5 months prior to the start date of the event. Please notify the Conference Secretariat if you have not received a notification by mid-July. If your abstract is accepted, one author is required to register for the workshop and present the paper as scheduled. Guidelines for preparing your oral and/or poster presentations will be sent after your abstract has been accepted.
Abstract Publication
Accepted abstracts will be published in the Program & Abstract Book. This will be distributed during the workshop and will be available as an enduring material after the workshop has concluded. Please note that the conference secretariat cannot be held responsible for any typing or language errors in the submitted abstracts as only the format of the abstracts will be changed and not the content.
VE and AME is the sole copyright holder of the workshop abstract book as a whole (also referred to as the Reviews in Antiviral Therapy & Infectious Diseases). The abstract authors will retain any and all copyright over their individual abstract. Information on copyright can be viewed in the abstract submission terms and conditions (see 'Terms and Conditions' above).
VE and AME is the sole copyright holder of the workshop abstract book as a whole (also referred to as the Reviews in Antiviral Therapy & Infectious Diseases). The abstract authors will retain any and all copyright over their individual abstract. Information on copyright can be viewed in the abstract submission terms and conditions (see 'Terms and Conditions' above).
Poster Presentation Guidelines
For this hybrid workshop, the following instructions apply in preparation of the poster presentation whether you attend the meeting in-person or virtually.
• You are requested to upload a 3-minute video and your poster in PDF on our Virtual Workshop Portal. You can record your presentation directly in PowerPoint or Zoom;
• Please display your abstract number in the upper right corner of your poster;
• After the workshop, the poster and recording will be made available on the workshop website;
• If you can participate in person, you are requested to bring a print of your poster;
• If you can participate in-person, you shall be present at your poster during the poster viewing session in the program;
• The measurements of the physical poster should not exceed A0 size (3ft x 4ft or 90 cm x 120 cm) posted in portrait format;
• If you can participate in-person, we advise you to prepare hand-outs of your poster on Letter or A4 format;
• Adhesive material for your physical poster will be provided by the conference secretariat;
• Hang your physical poster as early as possible. All posters must be displayed from the opening session to the closing of the workshop;
If you are not able to attend in-person, please contact us at eva.vamvounaki@amededu.com to let us know.
Uploading to the Virtual Workshop Portal
We ask that you upload your virtual poster and short video to the virtual workshop portal regardless of whether you will attend the workshop in person or virtually. In this way, all virtual participants can view your findings.
Poster
• Your poster must be a PDF in order for you to upload it.
• Make sure to upload your poster by Friday, 2 September 2022.
Video
• Your 3-minute video must be uploaded using a URL (website address).
• We advise that you upload your short presentation to YouTube (you can do this in a way that keeps it private) and take the URL from there.
• The video should be of you briefly presenting the poster. You are welcome to use slides but this is not mandatory.
• Make sure to upload your video by Friday, 2 September 2022.
• You are requested to upload a 3-minute video and your poster in PDF on our Virtual Workshop Portal. You can record your presentation directly in PowerPoint or Zoom;
• Please display your abstract number in the upper right corner of your poster;
• After the workshop, the poster and recording will be made available on the workshop website;
• If you can participate in person, you are requested to bring a print of your poster;
• If you can participate in-person, you shall be present at your poster during the poster viewing session in the program;
• The measurements of the physical poster should not exceed A0 size (3ft x 4ft or 90 cm x 120 cm) posted in portrait format;
• If you can participate in-person, we advise you to prepare hand-outs of your poster on Letter or A4 format;
• Adhesive material for your physical poster will be provided by the conference secretariat;
• Hang your physical poster as early as possible. All posters must be displayed from the opening session to the closing of the workshop;
If you are not able to attend in-person, please contact us at eva.vamvounaki@amededu.com to let us know.
Uploading to the Virtual Workshop Portal
We ask that you upload your virtual poster and short video to the virtual workshop portal regardless of whether you will attend the workshop in person or virtually. In this way, all virtual participants can view your findings.
Poster
• Your poster must be a PDF in order for you to upload it.
• Make sure to upload your poster by Friday, 2 September 2022.
Video
• Your 3-minute video must be uploaded using a URL (website address).
• We advise that you upload your short presentation to YouTube (you can do this in a way that keeps it private) and take the URL from there.
• The video should be of you briefly presenting the poster. You are welcome to use slides but this is not mandatory.
• Make sure to upload your video by Friday, 2 September 2022.
Oral Presentation Guidelines
For this hybrid workshop, the following instructions apply in the preparation of the oral presentation:
• You are requested to attend the workshop in person for your oral presentation. In case you cannot attend, we will ask you to present your abstract remotely;
• We have allocated a specific duration for your presentation. Chairs have been instructed to strictly adhere to these timelines, and therefore we advise you to rehearse your presentation;
• Submit your presentation on a USB thumb drive (please double-check your USB for computer viruses). You can submit your presentation to those seated at the technician table in the meeting room any time prior to your presentation, but no later than the break preceding your presentation slot;
• PCs will be used for the presentations. If you are working on a MAC computer, you need to format your presentation to a PC-compatible file and check the layout of your presentation before handing it in;
• The first slide of your presentation should display your conflict of interest declaration;
• Tips and tricks: avoid using animations, use common fonts (Arial), readable font size (>16), and clear colors; The screen ratio for this workshop is 16:9;
• We request that you go to the front of the room at least 5 minutes prior to the start of the session;
• In case the abstract(s) will be presented by someone else, please inform us at your earliest convenience, to allow us sufficient time to make corrections in the program.
• We encourage you to review our person-first language guidelines here.
• You are requested to attend the workshop in person for your oral presentation. In case you cannot attend, we will ask you to present your abstract remotely;
• We have allocated a specific duration for your presentation. Chairs have been instructed to strictly adhere to these timelines, and therefore we advise you to rehearse your presentation;
• Submit your presentation on a USB thumb drive (please double-check your USB for computer viruses). You can submit your presentation to those seated at the technician table in the meeting room any time prior to your presentation, but no later than the break preceding your presentation slot;
• PCs will be used for the presentations. If you are working on a MAC computer, you need to format your presentation to a PC-compatible file and check the layout of your presentation before handing it in;
• The first slide of your presentation should display your conflict of interest declaration;
• Tips and tricks: avoid using animations, use common fonts (Arial), readable font size (>16), and clear colors; The screen ratio for this workshop is 16:9;
• We request that you go to the front of the room at least 5 minutes prior to the start of the session;
• In case the abstract(s) will be presented by someone else, please inform us at your earliest convenience, to allow us sufficient time to make corrections in the program.
• We encourage you to review our person-first language guidelines here.
Support
Gold Level
Silver Level
Supported by Gilead who provided funding. Gilead has had no input into the content of the materials used at this meeting/conference.
Principal Supporter Level
Contributor Level
Support Our Initiative
Financial backing helps us deliver an impactful meeting experience for the benefit of healthcare professionals, researchers, and community representatives involved in Clinical Pharmacology of HIV, Hepatitis, and other Antiviral Drugs.
This collaboration plays a vital role in both the organizational as well as scientific success of the program.
To show your commitment to the cause and get in touch with us for a tailored support package, please contact Rikke Puggaard-Rode at Rikke.Rode@amededu.com.
Benefits of Support
By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.
- Symposium opportunities
- Non-commercial interviews with company representatives
- Verbal acknowledgment during the program
- Discounted and complimentary registrations for your representatives
- Company acknowledgment on digital meeting materials including but not limited to newsletters, flyers, the streaming platform, and our website
- Company acknowledgment on printed meeting materials including but not limited to banners and the program book
- Digital and printed advertising opportunities
- Social media shout-outs
- Logo on the conference bag
*Subject to the support level
Endorsers
Photo Gallery
Group Photo
Previous Editions
Previous Editions
- 22nd Edition - International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs, 2021, Virtual
- 21st Edition - International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs, 2020, Virtual
- 20th Edition - International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs, 2019, The Netherlands
- 19th Edition - International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs, 2018, United States
- 18th Edition - International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs, 2017, United States
- 17th Edition, International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs, 2016, United States
Top-Rated Materials from Previous Editions
Contribution of Pharmacology to HIV Cure - Angela Kashuba, BScPhm, PharmD, DABCP, FCP
International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs 2021
